ImaginAb Inc. an immuno-oncology imaging company.
ImaginAb Inc. is an immuno-oncology company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity.
The company’s clinical stage CD8+T Cell imaging agent is designed to non-invasively determine changes in CD8+T cell tumor infiltrates induced by immuno-oncological treatments. This approach has the potential to guide the development of immuno-modulatory agents as well as assess early on whether a patient responds to such a treatment. ImaginAb is also advancing a best-in-class imaging agent portfolio to improve cancer management and patient outcomes. ImaginAb’s products have the potential to improve patient care and lower healthcare costs.
We would welcome and look forward to meeting our current and potential partners at the SNMMI conference.